ArticleCancer diagnosis & prognosis
Factors Influencing Severe Hematologic Toxicity Following Niraparib Therapy in Patients With Ovarian Cancer.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation.Clinical pharmacokinetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Niraparib is a poly ADP ribose polymerase (PARP) inhibitor indicated for the maintenance therapy of ovarian cancer and the treatment of recurrent ovarian cancer. This study aimed to identify an indicator to predict severe hematologic toxicity after niraparib therapy. Patients and Methods: We retrospectively included 32 patients with advanced ovarian cancer who were administered niraparib at Ogaki Municipal Hospital (Ogaki, Japan) between January 2020 and December 2024. Univariate analyses were performed to evaluate the relationship between the patients' baseline characteristics and the development of severe hematologic toxicity. Significant variables in the univariate analysis, as well as age, were entered into the multivariate logistic regression model. The optimal cutoff values for significant variables were determined using receiver-operating characteristic (ROC) curve analyses. Results: Severe hematologic toxicity was independently associated with pre-treatment creatinine clearance (odds ratio=0.920; 95% confidence interval=0.823-0.998; p=0.045). The areas under the ROC curves of creatinine clearance at the time of the worst-grade hematologic toxicity before and during niraparib administration were assessed for their ability to predict severe hematologic toxicity. The area under the curves of creatinine clearance at the time of ≥grade 3 hematologic toxicity during niraparib therapy showed high accuracy, with a value of 0.809 (95% confidence interval=0.659-0.958). The calculated cutoff value using the creatinine clearance curve was 47.0 ml/min. Conclusion: Creatinine clearance is a risk factor for severe hematologic toxicity. A creatinine clearance value <47.0 ml/min may slightly increase the risk of this toxicity in patients with ovarian cancer receiving niraparib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.